Kastamonu Medical Journal regularly publishes internationally qualified issues in the field of Medicine in the light of up-to-date information.

EndNote Style
Original Article
Results of stereotactic radiosurgery in the treatment of radioresistant brain metastases
Aims: The incidence of brain metastases in patients with renal cell carcinoma (RCC) and malignant melanoma (MM) with radioresistant histologies is over 50%. Stereotactic radiodiosurgery (SRS) may be beneficial in treating radioresistant histologies. The effectiveness of SRS in terms of local control and survival rates in the treatment of patients with radioresistant brain metastases was the focus of our study.
Methods: A retrospective review of RCC and MM brain metastases treated with SRS between 2013 and 2020 was conducted. Local control rates, distant brain metastases free survival, and overall survival (OS) were study endpoints.
Results: 55 brain metastases were detected in 29 patients, 14 of whom were MM and 15 were RCC. The median follow-up time was 13 (1-89) months. The 1-y and 3-y actuarial local control rates were 82.4% and 59%, respectively. Increased size and volume of brain metastases were associated with progressive disease (p=0.041, p=0.002). Local control rates were increased in those receiving whole brain radiotherapy (WBRT) prior to SRS (0.008). The 1-y and 3-y distant brain metastases free survival were 87.7% and 60.2%, respectively, and increased in those receiving WBRT before SRS, but not statistically significant (p=0.403). The median OS was 8 months (HR: 1.79, 95% CI: 4.48-11.51). There was no difference in OS according to whether the primary disease diagnosis was RCC or MM (p=0.482). Patients with 1-2 brain metastases had better OS than patients with 3 or more brain metastases (p=0.029). Recursive partitioning analysis (RPA) and graded prognostic assessment (GPA) prognostic risk scores were significantly related to OS (p=0.001, p<0.001). OS worsened in patients who received WBRT before SRS compared to those who did not (0.035). OS increased statistically in patients who received immunotherapy (p=0.033).
Conclusion: Improvement in local control was found in patients with small tumor diameter and volume. The addition of WBRT to the SRS increased both local control and distant brain metastasis free survival. Regarding OS, multiple metastases, high RPA score, and low GPA score worsened OS. Another crucial observation is that a positive predictive effect on OS was detected in patients in whom immunotherapy was combined with SRS.

1. Lassman AB, DeAngelis LM. Brain metastases.Neurol Clin. 2003;21(1):1-23.doi:10.1016/s0733-8619(02)00035-x
2. Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiationtherapy with or without stereotactic radiosurgery boost for patientswith one to three brain metastases: phase III results of the RTOG 9508randomised trial.Lancet. 2004;363(9422):1665-1672. doi:10.1016/S0140-6736(04)16250-8
3. Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brainmetastases treated with radiosurgery or radiosurgery plus whole-brainirradiation: a randomised controlled trial.Lancet Oncol. 2009;10(11):1037-1044. doi:10.1016/S1470-2045(09)70263-3
4. Sahgal A, Aoyama H, Kocher M, et al. Phase 3 trials of stereotacticradiosurgery with or without whole-brain radiation therapy for 1 to 4brain metastases: individual patient data meta-analysis.Int J Radiat OncolBiol Phys. 2015;91(4):710-717. doi:10.1016/j.ijrobp.2014.10.024
5. Flanigan RC, Campbell SC, Clark JI, Picken MM. Metastatic renal cellcarcinoma.Curr Treat Options Oncol. 2003;4(5):385-390. doi:10.1007/s11864-003-0039-2
6. Tas F. Metastatic behavior in melanoma: timing, pattern, survival, andinfluencing factors.J Oncol. 2012;2012:647684. doi:10.1155/2012/647684
7. Buchsbaum JC, Suh JH, Lee SY, Chidel MA, Greskovich JF, Barnett GH.Survival by radiation therapy oncology group recursive partitioninganalysis class and treatment modality in patients with brain metastasesfrom malignant melanoma: a retrospective study.Cancer. 2002;94(8):2265-2272. doi:10.1002/cncr.10426
8. Halperin EC, Harisiadis L. The role of radiation therapy in the managementof metastatic renal cell carcinoma.Cancer. 1983;51(4):614-617.doi:10.1002/1097-0142(19830215)51:4&lt;614:aid-cncr2820510411&gt;3.0.co;2-j
9. Sin AH, Cardenas RJ, Vannemreddy P, Nanda A. Gamma knifestereotactic radiosurgery for intracranial metastases from conventionallyradioresistant primary cancers: outcome analysis of survival andcontrol of brain disease.South Med J. 2009;102(1):42-44. doi:10.1097/SMJ.0b013e318189acd3
10. Brown PD, Brown CA, Pollock BE, Gorman DA, Foote RL.Stereotactic radiosurgery for patients with &ldquo;radioresistant&rdquo; brainmetastases.Neurosurgery. 2008;62(Suppl 2):790-801. doi:10.1227/01.neu.0000316283.45242.e1
11. Yaeh A, Nanda T, Jani A, et al. Control of brain metastases fromradioresistant tumors treated by stereotactic radiosurgery.J Neurooncol.2015;124(3):507-514. doi:10.1007/s11060-015-1871-5
12. Lwu S, Goetz P, Monsalves E, et al. Stereotactic radiosurgery for thetreatment of melanoma and renal cell carcinoma brain metastases.OncolRep. 2013;29(2):407-412. doi:10.3892/or.2012.2139
13. Lo SS, Clarke JW, Grecula JC, et al. Stereotactic radiosurgery alone forpatients with 1-4 radioresistant brain metastases.Med Oncol. 2011;28(Suppl 1):S439-S444. doi:10.1007/s12032-010-9670-5
14. Kim KH, Lee MH, Cho KR, et al. The influence of histology on theresponse of brain metastases to gamma knife radiosurgery: a propensityscore-matched study.Acta Neurochir (Wien). 2018;160(12):2379-2386.doi:10.1007/s00701-018-3726-2
15. Yamamoto M, Serizawa T, Shuto T, et al. Stereotactic radiosurgery forpatients with multiple brain metastases (JLGK0901): a multi-institutionalprospective observational study.Lancet Oncol. 2014;15(4):387-395.doi:10.1016/S1470-2045(14)70061-0
16. Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumabversus Sunitinib in Advanced Renal-Cell Carcinoma.N Engl J Med.2018;378(14):1277-1290. doi:10.1056/NEJMoa1712126
17. Larkin J, Minor D, D&rsquo;Angelo S, et al. Overall survival in patients withadvanced melanoma who received nivolumab versus investigator&rsquo;schoice chemotherapy in checkmate 037: a randomized, controlled,open-label phase III trial.J Clin Oncol. 2018;36(4):383-390. doi:10.1200/JCO.2016.71.8023
18. World Medical Association. World Medical Association Declarationof Helsinki. Ethical principles for medical research involving humansubjects.Bull World Health Organ. 2001;79(4):373-374.
19. Agboola O, Benoit B, Cross P, et al. Prognostic factors derived fromrecursive partition analysis (RPA) of Radiation Therapy OncologyGroup (RTOG) brain metastases trials applied to surgically resectedand irradiated brain metastatic cases.Int J Radiat Oncol Biol Phys.1998;42(1):155-159. doi:10.1016/s0360-3016(98)00198-9
20. Sperduto PW, Kased N, Roberge D, et al. Summary report on the gradedprognostic assessment: an accurate and facile diagnosis-specific toolto estimate survival for patients with brain metastases.J Clin Oncol.2012;30(4):419-425. doi:10.1200/JCO.2011.38.0527
21. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluationcriteria in solid tumours: revised RECIST guideline (version 1.1).Eur JCancer. 2009;45(2):228-247. doi:10.1016/j.ejca.2008.10.026
22. Selek U, Chang EL, Hassenbusch SJ 3rd, et al. Stereotactic radiosurgicaltreatment in 103 patients for 153 cerebral melanoma metastases.Int J RadiatOncol Biol Phys. 2004;59(4):1097-1106. doi:10.1016/j.ijrobp.2003.12.037
23. Zaorsky NG, Lehrer EJ, Kothari G, Louie AV, Siva S. Stereotactic ablativeradiation therapy for oligometastatic renal cell carcinoma (SABRORCA): a meta-analysis of 28 studies.Eur Urol Oncol. 2019;2(5):515-523.doi:10.1016/j.euo.2019.05.007
24. Sayan M, Zoto Mustafayev T, Sahin B, et al. Evaluation of responseto stereotactic radiosurgery in patients with radioresistant brainmetastases.Radiat Oncol J. 2019;37(4):265-270. doi:10.3857/roj.2019.00409
25. Maranzano E, Casale M, Rispoli R, et al. LINAC-based radiosurgeryfor melanoma, sarcoma and renal cell carcinoma brain metastases.J Neurosurg Sci. 2020;64(1):37-43. doi:10.23736/S0390-5616.16.03745-0
26. Bagshaw HP, Ly D, Suneja G, Jensen RL, Shrieve DC. Local controlof melanoma brain metastases treated with stereotactic radiosurgery.J Radiosurg SBRT. 2016;4(3):181-190.
27. Fokas E, Henzel M, Hamm K, Surber G, Kleinert G, Engenhart-Cabillic R.Radiotherapy for brain metastases from renal cell cancer: should whole-brain radiotherapy be added to stereotactic radiosurgery?: analysis of 88patients.Strahlenther Oncol. 2010;186(4):210-217. doi:10.1007/s00066-010-2055-z
28. Yomo S, Oda K, Oguchi K. Effectiveness of immune checkpointinhibitors in combination with stereotactic radiosurgery for patientswith brain metastases from renal cell carcinoma: inverse probabilityof treatment weighting using propensity scores.J Neurosurg. 2022;1-9.doi:10.3171/2022.9.JNS221215
29. Chen L, Douglass J, Kleinberg L, et al. Concurrent immune checkpointinhibitors and stereotactic radiosurgery for brain metastases in non-smallcell lung cancer, melanoma, and renal cell carcinoma.Int J Radiat OncolBiol Phys. 2018;100(4):916-925. doi:10.1016/j.ijrobp.2017.11.041
30. Shanker MD, Garimall S, Gatt N, et al. Stereotactic radiosurgery formelanoma brain metastases: concurrent immune checkpoint inhibitortherapy associated with superior clinicoradiological response outcomes.J Med Imaging Radiat Oncol. 2022;66(4):536-545. doi:10.1111/1754-9485.13403
Volume 3, Issue 3, 2023
Page : 122-131